Use of SELDI MS to discover and identify potential biomarkers of toxicity in InnoMed PredTox: A multi‐site, multi‐compound study

A serious bottleneck in the drug development pipeline is the inability of current pre‐clinical toxicology evaluation methods to predict early on, and with good accuracy, that a drug candidate will have to be removed from development due to toxicology/safety issues. The InnoMed PredTox consortium attempted to address this issue by assessing the value of using molecular profiling techniques (proteomics, transcriptomics, and metabonomics), in combination with conventional toxicology measurements, on decision making earlier in pre‐clinical safety evaluation. In this study, we report on the SELDI‐TOF‐MS proteomics component of the InnoMed PredTox project. In this large scale, multi‐site, multi‐compound study, tissue and plasma samples from 14‐day in vivo rat experiments conducted for 16 hepato‐ and nephro‐toxicants with known toxicology endpoints (including 14 proprietary compounds and 2 reference compounds) were analyzed by SELDI‐TOF‐MS. We have identified seven plasma proteins and four liver proteins which were shown to be modulated by treatment, and correlated with histopathological evaluations and can be considered potential biomarker candidates for the given toxicology endpoints. In addition, we report on the intra‐ and inter‐site variations observed based on measurements from a reference sample, and steps that can be taken to minimize this variation.

[1]  E. Petricoin,et al.  Toxicoproteomics: Serum Proteomic Pattern Diagnostics for Early Detection of Drug Induced Cardiac Toxicities and Cardioprotection , 2004, Toxicologic pathology.

[2]  J. Ozer,et al.  The current state of serum biomarkers of hepatotoxicity. , 2008, Toxicology.

[3]  L. Lomas,et al.  Application of surface‐enhanced laser desorption/ionization technology to the detection and identification of urinary parvalbumin‐α: A biomarker of compound‐induced skeletal muscle toxicity in the rat , 2002, Electrophoresis.

[4]  Barbara A Wetmore,et al.  Toxicoproteomics: proteomics applied to toxicology and pathology. , 2004, Toxicologic pathology.

[5]  D. Baunsgaard,et al.  Mechanisms of hydrazine toxicity in rat liver investigated by proteomics and multivariate data analysis , 2004, Proteomics.

[6]  F. Fonnum,et al.  Comparative hepatic gene expression profiling of rats treated with 1H,1H,2H,2H-heptadecafluorodecan-1-ol or with pentadecafluorooctanoic acid. , 2008, Physiological genomics.

[7]  P. Righetti,et al.  The ProteoMiner in the proteomic arena: a non-depleting tool for discovering low-abundance species. , 2008, Journal of proteomics.

[8]  Ben C Collins,et al.  Use of proteomics for the discovery of early markers of drug toxicity , 2007, Expert opinion on drug metabolism & toxicology.

[9]  O John Semmes,et al.  Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization‐time of flight (SELDI‐TOF) mass spectrometry: Multi‐institution correlation of spectra and identification of biomarkers , 2005, Proteomics.

[10]  M. Wong,et al.  Glutathione S-transferases--a review. , 1999, Current medicinal chemistry.

[11]  B. Merrick.  The plasma proteome, adductome and idiosyncratic toxicity in toxicoproteomics research. , 2008, Briefings in functional genomics & proteomics.

[12]  Ben van Ommen,et al.  Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology , 2005, Expert review of proteomics.

[13]  Rainer Cramer,et al.  Serum Peptide Profiling using MALDI Mass Spectrometry , 2007, Proteomics.

[14]  S. Weinberger,et al.  Current developments in SELDI affinity technology. , 2004, Mass spectrometry reviews.

[15]  Martin Shaw.  The use of histologically defined specific biomarkers in drug development with special reference to the glutathione S-transferases. , 2005, Cancer Biomarkers.

[16]  Y. Chao,et al.  Phenobarbital induces rat liver apolipoprotein A-I mRNA. , 1985, Molecular pharmacology.

[17]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[18]  Annette Kopp-Schneider,et al.  Comparison of software tools to improve the detection of carcinogen induced changes in the rat liver proteome by analyzing SELDI-TOF-MS spectra. , 2006, Journal of proteome research.

[19]  Antoine H P America,et al.  Comparative LC‐MS: A landscape of peaks and valleys , 2008, Proteomics.

[20]  R. Aebersold,et al.  Scoring proteomes with proteotypic peptide probes , 2005, Nature Reviews Molecular Cell Biology.

[21]  C. Hogstrand,et al.  Application of genomics and proteomics for study of the integrated response to zinc exposure in a non-model fish species, the rainbow trout. , 2002, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

[22]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[23]  L. Weber,et al.  Hepatocyte Damage Induced by Carbon Tetrachloride: Inhibited Lipoprotein Secretion and Changed Lipoprotein Composition , 2001, Zeitschrift fur Naturforschung. C, Journal of biosciences.

[24]  M. Karas,et al.  Use of two‐dimensional gel electrophoresis in predictive toxicology: Identification of potential early protein biomarkers in chemically induced hepatocarcinogenesis , 2005, Proteomics.

[25]  L. Babiss,et al.  Toxicogenomics in predictive toxicology in drug development. , 2004, Chemistry & biology.

[26]  J. Albrethsen.  Reproducibility in protein profiling by MALDI-TOF mass spectrometry. , 2007, Clinical chemistry.

[27]  William M. Gallagher,et al.  Creation of a digital slide and tissue microarray resource from a multi-institutional predictive toxicology study in the rat: an initial report from the PredTox group. , 2008, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[28]  Michael D. Waters,et al.  Toxicogenomics and systems toxicology: aims and prospects , 2004, Nature Reviews Genetics.

[29]  Pier Giorgio Righetti,et al.  Blue silver: A very sensitive colloidal Coomassie G‐250 staining for proteome analysis , 2004, Electrophoresis.

[30]  B K Larsen,et al.  The Potential of Ecotoxicoproteomics in Environmental Monitoring: Biomarker Profiling in Mussel Plasma Using Proteinchip Array Technology , 2006, Journal of toxicology and environmental health. Part A.

[31]  R. Townsend,et al.  Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy. , 2005, Clinical chemistry.

[32]  Proteomic analysis of human breast cell lines using SELDI-TOF MS shows that mixtures of estrogenic compounds exhibit simple similar action (concentration additivity). , 2008, Toxicology letters.

[33]  W. Gallagher,et al.  Omic profiling for drug safety assessment: current trends and public-private partnerships. , 2009, Drug discovery today.

[34]  Wayne F. Patton,et al.  A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. , 2007, Clinical chemistry.

[35]  N. Anderson,et al.  The Human Plasma Proteome: History, Character, and Diagnostic Prospects , 2003, Molecular & Cellular Proteomics.

[36]  Lee Weng,et al.  Toxicogenomic analysis methods for predictive toxicology. , 2006, Journal of pharmacological and toxicological methods.

[37]  W. Vach,et al.  Serum protein profiling by solid phase extraction and mass spectrometry: A future diagnostics tool? , 2009, Proteomics.

[38]  J. Kramer,et al.  The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates , 2007, Nature Reviews Drug Discovery.

[39]  Elaine Holmes,et al.  Systems toxicology: integrated genomic, proteomic and metabonomic analysis of methapyrilene induced hepatotoxicity in the rat. , 2006, Journal of proteome research.

[40]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[41]  A. Bosserhoff,et al.  Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. , 2006, Oncology reports.